The late-breaking presentation on the COMBO study, a randomized control trial, will highlight two-year outcomes demonstrating the durable effectiveness of the WaveWriter Spinal Cord Stimulator (SCS) System capable of delivering combination therapy - the ability to layer multiple waveforms and modalities simultaneously. Combination therapy is designed to offer more opportunities to customize SCS therapy and optimize outcomes.
In addition,
'The data we'll share this year at NANS is a testament to the breadth and depth of the randomized, controlled and real-world evidence of our portfolio and therapies,' said
Patel added, 'The condition of chronic pain is complex, and because of neuroplasticity, it changes over time. As a result, you need an agile platform with multiple options that adapts with the changing needs of the patient. No one patient living with chronic pain is the same so we're continuously working to advance and transform personalized therapies for the future to help patients live healthier lives.'
Featured Abstracts
Oral Presentations:
COMBO Randomized Control Trial: Two-Year Outcomes of an SCS System Capable of Simultaneous Delivery of Multiple Modalities to be presented by
Prospective, Multi-Center Evaluation of
Paper Posters:
RAPID: An International, Prospective, Multicenter Study of Radiofrequency Ablation Outcomes in Chronic Pain Patients,
Comprehensive Digital Tools to Improve Access to Care and Treatment Efficiency for Spinal Cord Stimulation, Vucetic et al.
Modeling and Measurement of the Effect of
The Biomechanics of Interspinous Spacers, Whang et al.
Publication will be made available after the release of the data presentations.
About the Boston Scientific Chronic Pain Portfolio
Where many 'one-size fits all' treatments fail to provide long-term relief,
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like 'anticipate,' 'expect,' 'project,' 'believe,' 'plan,' 'estimate,' 'intend' and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the
Contact:
Media
T: +1.415.730.2310
E: jessica.sachariason@bsci.com
Investor
T: +1.508.683.4479
E: lauren.tengler@bsci.com
(C) 2022 Electronic News Publishing, source